DeepChek® HBV and DeepChek® HCV Now Available In Illumina’s BaseSpace Apps

LUXEMBOURG VILLE, Luxembourg, Jan. 5, 2015 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL) S.A. today announced it has added two new DeepChek® applications to BaseSpace Apps, Illumina’s dedicated applications store and cloud-based informatics community dedicated to advancing genomic analysis.

These two new research use only modules are dedicated viral hepatitis B (HBV) and hepatitis C (HCV) mapping tools for next-generation sequencing analysis. Leveraging ABL’s virology expertise, the new apps make an important contribution to cloud-based genomics research. They use a fully integrated, dynamic genotype/resistance testing solution from distinct HBV and HCV resistance testing interpretive algorithms developed by several research institutions around the world.

“It seemed logical for ABL to bring a comprehensive portfolio to BaseSpace, enabling researchers to advance their findings on major viruses like HBV and HCV, using the same system with extended features of storage, processing, and analysis,” said Dr Chalom B. Sayada, CEO of ABL. “We are committed to bringing new features to the BaseSpace portfolio and to further expand innovations in microbiology, bringing researchers new tools and letting them target new discoveries in virology.”

Today no cure is available for the 240 million of people infected by HBV and the most important limitation of existing treatments is due to drug-resistant mutant viruses. New direct-acting antiviral drugs may help in finding a way to neutralize HBV and HCV but this can only happen after an advanced focused testing can be made to determine patients’ viral profiles. The research required to bring about these advances in therapeutics are exactly what the DeepChek® apps enable.

Next-generation sequencing on Illumina instruments allows the identification of HBV and HCV viral dynamics within a sample. Researchers can perform the analysis through the DeepChek® pipeline, with sample data streamed directly from the instrument to BaseSpace. Using the apps, researchers can track viral populations and identify changes within genomes as well as the expression of dual infections and co-infection. The full informatics workflow takes only a few minutes to complete for each sample.

Informatics solutions available through BaseSpace Apps allow customers to utilize the tools from a growing community of academic, commercial, and open source providers.

About ABL:

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL’s products also received CE-marking for IVD use.

Media Contact: Chalom B. SAYADA, Advanced Biological Laboratories, +35226388921,

Help employers find you! Check out all the jobs and post your resume.